Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Variation in Plasma Levels of TRAF2 Protein During Development of Squamous Cell Carcinoma of the Oral Tongue

X. Gu, P. Coates, L. Wang, B. Erdogan, A. Salehi, N. Sgaramella, K. Zborayova, K. Nylander

. 2021 ; 11 (-) : 753699. [pub] 20211123

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22001245

As early detection is crucial for improvement of cancer prognosis, we searched for biomarkers in plasma from individuals who later developed squamous cell carcinoma of the oral tongue (SCCOT) as well as in patients with an already established SCCOT. Levels of 261 proteins related to inflammation and/or tumor processes were measured using the proximity extension assay (PEA) in 179 plasma samples (42 collected before diagnosis of SCCOT with 81 matched controls; 28 collected at diagnosis of SCCOT with 28 matched controls). Statistical modeling tools principal component analysis (PCA) and orthogonal partial least square - discriminant analysis (OPLS-DA) were applied to provide insights into separations between groups. PCA models failed to achieve group separation of SCCOT patients from controls based on protein levels in samples taken prior to diagnosis or at the time of diagnosis. For pre-diagnostic samples and their controls, no significant OPLS-DA model was identified. Potentials for separating pre-diagnostic samples collected up to five years before diagnosis (n = 15) from matched controls (n = 28) were seen in four proteins. For diagnostic samples and controls, the OPLS-DA model indicated that 21 proteins were important for group separation. TNF receptor associated factor 2 (TRAF2), decreased in pre-diagnostic plasma (< 5 years) but increased at diagnosis, was the only protein showing altered levels before and at diagnosis of SCCOT (p-value < 0.05). Taken together, changes in plasma protein profiles at diagnosis were evident, but not reliably detectable in pre-diagnostic samples taken before clinical signs of tumor development. Variation in protein levels during cancer development poses a challenge for the identification of biomarkers that could predict SCCOT development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001245
003      
CZ-PrNML
005      
20220112153536.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2021.753699 $2 doi
035    __
$a (PubMed)34888239
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gu, Xiaolian $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
245    10
$a Variation in Plasma Levels of TRAF2 Protein During Development of Squamous Cell Carcinoma of the Oral Tongue / $c X. Gu, P. Coates, L. Wang, B. Erdogan, A. Salehi, N. Sgaramella, K. Zborayova, K. Nylander
520    9_
$a As early detection is crucial for improvement of cancer prognosis, we searched for biomarkers in plasma from individuals who later developed squamous cell carcinoma of the oral tongue (SCCOT) as well as in patients with an already established SCCOT. Levels of 261 proteins related to inflammation and/or tumor processes were measured using the proximity extension assay (PEA) in 179 plasma samples (42 collected before diagnosis of SCCOT with 81 matched controls; 28 collected at diagnosis of SCCOT with 28 matched controls). Statistical modeling tools principal component analysis (PCA) and orthogonal partial least square - discriminant analysis (OPLS-DA) were applied to provide insights into separations between groups. PCA models failed to achieve group separation of SCCOT patients from controls based on protein levels in samples taken prior to diagnosis or at the time of diagnosis. For pre-diagnostic samples and their controls, no significant OPLS-DA model was identified. Potentials for separating pre-diagnostic samples collected up to five years before diagnosis (n = 15) from matched controls (n = 28) were seen in four proteins. For diagnostic samples and controls, the OPLS-DA model indicated that 21 proteins were important for group separation. TNF receptor associated factor 2 (TRAF2), decreased in pre-diagnostic plasma (< 5 years) but increased at diagnosis, was the only protein showing altered levels before and at diagnosis of SCCOT (p-value < 0.05). Taken together, changes in plasma protein profiles at diagnosis were evident, but not reliably detectable in pre-diagnostic samples taken before clinical signs of tumor development. Variation in protein levels during cancer development poses a challenge for the identification of biomarkers that could predict SCCOT development.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coates, Philip $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia
700    1_
$a Wang, Lixiao $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Erdogan, Baris $u Department of Clinical Sciences, Umeå University, Umeå, Sweden
700    1_
$a Salehi, Amir $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Sgaramella, Nicola $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Zborayova, Katarina $u Department of Clinical Sciences, Umeå University, Umeå, Sweden
700    1_
$a Nylander, Karin $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 11, č. - (2021), s. 753699
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34888239 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153532 $b ABA008
999    __
$a ind $b bmc $g 1745414 $s 1152392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c - $d 753699 $e 20211123 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20220107

Find record

Citation metrics

Archiving options